Cutaneous adverse events in children treated with vemurafenib for refractory <i>BRAF</i>^V600E mutated Langerhans cell histiocytosis

Abstract

At doses used for pediatric LCH, CAEs are frequent but rarely severe and have little impact on the continuation of treatment when managed appropriately. Regular dermatological follow-up is essential to manage CAEs and screen for possible induced skin tumors.